https://sa.m.netdania.com/news/Convergence%20Investment%20Partners%20LLC%20Grows%20Stock%20Holdings%20in%20Halozyme%20Therapeutics,%20Inc.%20(NASDAQ:HALO)/Buzz%20FX/%7Bna:%5B%7Bt:%5B%22BUZZ_FX_GF%22%5D%7D%5D,hf:0%7D/tcnews/a1f5aea77f8bfcb720116161687fda491d128fe8@%7B%22Syms%22:%5B%5D,%22Inf%22:%7B%22PBL%22:%22MarketBeat%22%7D%7D/1739964371
Convergence Investment Partners LLC Grows Stock Holdings in Halozyme Therapeutics, Inc....
Convergence Investment Partners LLC Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - NetDania News
investment partnershalozyme therapeuticsconvergencellcgrows
https://www.finanznachrichten.de/aktien-analysen/halozyme-therapeutics-inc.htm
HALOZYME THERAPEUTICS-AKTIE kaufen? Analysen, Kursziele & Empfehlungen zu A0DLHS
HALOZYME THERAPEUTICS-Aktie jetzt kaufen? Analysen und Kursziele:
halozyme therapeuticsaktiekaufenanalysenempfehlungen
https://pitchgrade.com/companies/halozyme-therapeutics-inc
Halozyme Therapeutics: Business Model, SWOT Analysis, and Competitors 2026 - PitchGrade
Comprehensive 2026 analysis of Halozyme Therapeutics: business model, SWOT analysis, competitors, and real financial data ($1.40B revenue, $7.95B market cap)...
halozyme therapeuticsbusiness modelswot analysiscompetitors
https://catalystalert.io/news/ada6b4f2-1237-4d64-a321-100129584819
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road | CatalystAlert
May 6, 2026 - Opinion piece analyzing Halozyme Therapeutics' business model as a drug-delivery platform generating royalty income. No material company announcements, clinical
halozyme therapeuticsdrug deliverytoll roadroyaltyengine
https://www.home.saxo/de-ch/markets/stocks/halo-xnas
Halozyme Therapeutics Inc. aktie | Saxo Bank Schweiz
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
halozyme therapeuticssaxo bankincaktieschweiz
https://www.sahmcapital.com/news/content/halozyme-therapeutics-signs-collaboration-license-deal-with-vertex-pharmaceuticals-for-hypercon-2026-04-07
Halozyme Therapeutics Signs Collaboration, License Deal With Vertex Pharmaceuticals For Hypercon
Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme or the Company) today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a...
halozyme therapeuticsvertex pharmaceuticalssignscollaborationlicense
https://health.economictimes.indiatimes.com/news/pharma/halozyme-therapeutics-to-acquire-antares-pharma-in-all-cash-deal/90843060
Halozyme Therapeutics to acquire Antares Pharma in all-cash deal, ETHealthworld
The transaction, which values Antares at $960 million, demonstrates Halozyme's commitment to drug delivery.
halozyme therapeuticsin allacquireantarespharma
https://www.benzinga.com/insights/earnings/24/02/37202069/earnings-preview-halozyme-therapeutics
Earnings Preview: Halozyme Therapeutics - Halozyme Therapeutics (NASDAQ:HALO) - Benzinga
earnings previewhalozyme therapeuticsnasdaqbenzinga
https://marketchameleon.com/Overview/HALO/ATMStraddleHistory/
HALO At-the-Money Straddle Performance Halozyme Therapeutics
View historical at-the-money option straddle performance for Halozyme Therapeutics (HALO), including different delta-neutral hedging techniques and...
at the moneystraddle performancehalozyme therapeutics
https://www.edgehound.com/stocks/HALO/
Halozyme Therapeutics, Inc. (HALO) stock price, ideas, forecast, news 2026
Find the latest Halozyme Therapeutics, Inc. (HALO) stock quote, history, news and other vital information to help you with your stock trading and investing.
halozyme therapeuticsstock priceforecast newsincideas
https://theorg.com/org/halozyme-therapeutics/teams/sales-and-account-management
Halozyme Therapeutics - Sales and Account Management | The Org
The Sales and Account Management team at Halozyme Therapeutics is responsible for driving sales growth and managing relationships with healthcare providers and...
halozyme therapeuticsaccount managementsales
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/investors-in-halozyme-therapeutics-nasdaqhalo-have-seen-impr
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past...
Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) shareholders might be concerned after seeing the share price drop 17% in...
halozyme therapeuticshave seeninvestorsnasdaqimpressive
https://www.biospace.com/halozyme-therapeutics-inc-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference
Halozyme Therapeutics, Inc. To Present At The Bank of America Merrill Lynch 2015 Health Care...
bank of americahalozyme therapeuticsto presentmerrill lynchhealth care
https://convention.bio.org/participating-companies/halozyme-therapeutics-inc
Halozyme Therapeutics, Inc - BIO International Convention 2026
bio international conventionhalozyme therapeuticsinc
https://lifesciencetracker.com/entries/halozyme-therapeutics-10-q-5-9-23/
Halozyme Therapeutics 10-Q (5/9/23) - Incubate Investment Tracker
halozyme therapeuticsinvestment trackerqincubate